Evidence map›Paper›PMID 42145644›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

Linda Karlsson, Olof Strandberg, Ruben Smith, Weizhong Tang, Ida Arvidsson, Kalle Åström, Kevin Oliveira Hauer, Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist and 13 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Linda KarlssonClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID 0000-0002-0630-772X
Olof StrandbergClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Ruben SmithClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Weizhong TangClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Ida ArvidssonCentre for Mathematical Sciences, Lund University, Lund, Sweden.
Kalle ÅströmCentre for Mathematical Sciences, Lund University, Lund, Sweden.
Kevin Oliveira HauerClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Philip B VergheseC2N Diagnostics LLC, St Louis, MO, USA.
Joel B BraunsteinC2N Diagnostics LLC, St Louis, MO, USA.
Alzheimer’s Disease Neuroimaging Initiative
PREVENT-AD Research Group
Gregory KleinPharma Research and Early Development, F Hoffmann-La Roche Ltd., Basel, Switzerland.
Sergey ShcherbininEli Lilly and Company, Indianapolis, Indiana, USA.
William J JagustDepartment of Neuroscience, University of California, Berkeley, California, USA.
Sylvia VilleneuveCentre for Studies in the Prevention of Alzheimer's Disease, Douglas Mental Health Institute, McGill University, Montreal, QC, Canada.
Renaud La JoieDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.ORCID 0000-0003-2581-8100
Gil D RabinoviciDepartment of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Jacob W VogelClinical Memory Research Unit, SciLifeLab, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.ORCID 0000-0001-8467-7286

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settingsR01AG083740 · NIA · LUNDS UNIVERSITET · PI Sebastian Palmqvist · 2023 to 2026
$1.9M
NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG083740NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Tau protein aggregation in the brain is a hallmark of Alzheimer's disease (AD). Positron emission tomography (PET) is the only in vivo method to visualize tau pathology and estimate both its burden and regional distribution, but the use of tau-PET is constrained by high cost and limited accessibility. Here, we develop a deep learning model to synthesize tau-PET scans from more accessible data: structural magnetic resonance imaging (MRI), demographics, and when available, blood biomarkers. We included 5,191 participants across the AD continuum or with another neurological disorder from 13 cohorts (mean age 70 years, 51% female) and optimized a 3D U-Net neural network with residual and attention units for this task. In held-out test data, synthetic tau-PET reliably modeled tau burden, with correlations of R=0.77-0.86 with true tau-PET across individuals in common AD regions of interest. Spatial similarity between synthetic and true tau-PET was likewise high, with mean regional correlation of R=0.75. Synthetic scans also captured clinically meaningful prognostic information comparable to true tau-PET, including distinction between early (HR=12, p<0.001) and late (HR=45, p<0.001) stages of tau accumulation. These findings demonstrate that clinically informative synthetic tau-PET scans can be generated from widely available modalities using deep learning, potentially offering a scalable and cost-effective approach for estimating tau AD pathology in the brain.

Identifiers

PMID42145644
PMCPMC13174752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.